Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Centessa Pharmaceuticals (CNTA) Accumulated Depreciation & Amortization (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Accumulated Depreciation & Amortization for 4 consecutive years, with $680000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 4.49% to $680000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $680000.0, a 4.49% decrease, with the full-year FY2024 number at $942000.0, up 16.3% from a year prior.
  • Accumulated Depreciation & Amortization was $680000.0 for Q3 2025 at Centessa Pharmaceuticals, up from $443000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $942000.0 in Q4 2024 to a low of $28000.0 in Q1 2022.
  • A 4-year average of $387533.3 and a median of $326000.0 in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 518.32% in 2023, then fell 9.58% in 2025.
  • Centessa Pharmaceuticals' Accumulated Depreciation & Amortization stood at $131000.0 in 2022, then surged by 518.32% to $810000.0 in 2023, then increased by 16.3% to $942000.0 in 2024, then fell by 27.81% to $680000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Accumulated Depreciation & Amortization are $680000.0 (Q3 2025), $443000.0 (Q2 2025), and $217000.0 (Q1 2025).